Heloisa P. Soares,
MD, PhD
Languages Spoken: English, Portuguese, Spanish
Dr. Heloisa Soares is a medical oncologist with a focus in GI cancers and neuroendocrine tumors. She is an assistant professor at the Huntsman Cancer Institute (HCI) at University of Utah. Dr. Soares received her medical degree at Faculdade de Medicine do ABC in Brazil, where she was born. She completed her residency training at the Mount Sinai Medical Center of Florida and her hematology-oncology fellowship training and PhD in molecular biology at UCLA. Dr. Soares has neuroendocrine tumors and gastrointestinal (GI) cancers as the major focus of her research and clinical activities. She serves as the co-physician leader in the GI Clinical Trials Research Group at HCI. In 2019, she was elected as a member of the board of directors for The North American Neuroendocrine Tumor Society (NANETS), where she is also a member of the guidelines and communications committees. Additionally, she is a member of the NCI NET taskforce and member of SWOG and NRG cooperative groups. In 2018, Dr. Soares was named one of 40 Under 40 in Cancer, an awards program identifying and recognizing the contributions being made across the field of oncology by individuals under the age of 40 years old by the he Lynx Group™ and McGivney Global Advisors. Dr. Soares was awarded the NANETS 2020 Theranostics Investigator Scholarship (NTIG).
Dr. Soares is a passionate advocate to patients and has, along many other patient-centered activities, volunteered at the ASCO Advocacy Summit on Capital Hill and had the opportunity to meet members of congress and advocate to improve patient care.
You can follow her on twitter as @helops79
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor (Clinical) |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Medical Oncology) Educational Commission for Foreign Medical Graduates |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.8/ 5
Care provider's explanation of condition/problem
4.7/ 5
Care provider's effort to include me in decisions
4.7/ 5
Wait time at clinic
4.2/ 5
Care provider's concern for questions & worries
4.8/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
July 31, 2021
HUNTSMAN CANCER CENTER
Dr. Soares is excellent, both in terms of her subject knowledge and her ability to communicate on a very human level with the patient.
UofU Patient
July 26, 2021
HUNTSMAN CANCER CENTER
No issues
UofU Patient
July 23, 2021
HUNTSMAN CANCER CENTER
Although surprised at residual from gall bladder surgery and lack of full recovery from symptoms, Dr. Soares's assurance of flow up with the GI doctor gave me hope I may improve in the future. Dr. Soares IS the light.
UofU Patient
July 16, 2021
HUNTSMAN CANCER CENTER
Dr. Soares is in a class by herself. Incredible expertise and personal concern for her patients.
UofU Patient
July 01, 2021
HUNTSMAN CANCER CENTER
Top of the line. Never in my life, me, my wife & children have received the information that these staff gives.
UofU Patient
June 23, 2021
HUNTSMAN CANCER CENTER
Dr. Soares came highly recommended. She answered my questions. However for whatever reason during my appointment she seemed distracted and preoccupied. She glanced at the clock at least twice so we felt rushed, and when I made a comment that I was concerned we were taking too much time she commented she did have another patient she needed to see. This was a HUGE appointment for us. It was the appointment when we would be discussing what my biopsy showed, what it all meant and what treatment options I had and why one treatment was recommended and another wasn't and side affects and staging and what my prognosis was and if it was different with different treatments and what my quality of life might or might not be. My whole world has been turned upside down with my diagnosis of cancer, especially because this cancer is terminal. I didn't ask how long this appointment was going to be. I assumed it would be a long one so we would have time to talk and figure things out. Our first one with Dr Soares was virtual and because I had not had the biopsy yet there was not a lot we could realistically talk about. Everything in my mind was waiting on this second appointment. She knew information and was pleasant, but I didn't feel like she cared abt me as a person at all. I need a dr following me who I know has my best interest at heart, that I can depend on to care abt what is happening to me, who will do the best they can to take care of me during this tough journey.
UofU Patient
June 20, 2021
HUNTSMAN CANCER CENTER
Dr. Soares was incredible. She dug deeper than any doctor has and found records and test results that shed new light on the abdominal pain I have had for 6 years. I am so happy - I searched nationwide to find her, and found here here at the U, just blocks from my home downtown. Her expertise, her knowledge, her willingness to answer questions, and her communication skills and trilingual skills, are amazing and I benefitted from all of them. I am so happy to finally get the answers I needed from a specialist in the rare and confusing medical condition I faced. Mil gracias, muito obrigado, Dr. Soares!
UofU Patient
June 15, 2021
HUNTSMAN CANCER CENTER
Caught off guard with scans and what they showed Fear of not knowing if I'm going to live a while or am I limited
UofU Patient
June 04, 2021
HUNTSMAN CANCER CENTER
very caring and skilled doctor
UofU Patient
May 26, 2021
HUNTSMAN CANCER CENTER
Dr. Soares is amazing!
UofU Patient
May 23, 2021
HUNTSMAN CANCER CENTER
My appointment seems kind of rushed through.
UofU Patient
May 23, 2021
HUNTSMAN CANCER CENTER
I should have had my questions more in depth, some questions were answered but not all.
UofU Patient
May 06, 2021
HUNTSMAN CANCER CENTER
As always, exceptional health care and genuine concern for patients.
UofU Patient
April 30, 2021
HUNTSMAN CANCER CENTER
had hope of better outcome but that is what is it is. no fault of the doctor.
UofU Patient
April 02, 2021
HUNTSMAN CANCER CENTER
I am getting the best care possible!
UofU Patient
March 04, 2021
HUNTSMAN CANCER CENTER
I couldn't have hoped for a better team of doctor and nurses!
UofU Patient
February 25, 2021
HUNTSMAN CANCER CENTER
Dr. Soares is very knowledgeable about the condition and knows and understands the best action for support and treatment. at the same time she is very empathetic and personal. She's an excellent doctor and health practitioner. I have full confidence in her abilities and decisions.
UofU Patient
February 21, 2021
HUNTSMAN CANCER CENTER
As I said before, very well done by all.
UofU Patient
January 15, 2021
HUNTSMAN CANCER CENTER
always keeps us in the loop including our daughter and even calls our daughter to inform her of how things are going
UofU Patient
January 15, 2021
HUNTSMAN CANCER CENTER
Exceptional in every way
UofU Patient
January 01, 2021
HUNTSMAN CANCER CENTER
I was at fastrack
UofU Patient
December 30, 2020
HUNTSMAN CANCER CENTER
Since my husband was present in the room for the entire visit, it would have been helpful to have a private discussion with my him before making big decisions. I didn't ask for time and time wasn't offered. However, I do like and appreciate my Doctors' efforts on my behalf. They are terrific individuals.
UofU Patient
December 29, 2020
HUNTSMAN CANCER CENTER
I have been lucky to have top-notch physicians at high-quality institutions. Dr. Soares was in the position of having to take over many years of work of other Oncologists. She's jumped right in, did all of the preparatory work to see a complicated patient, and quickly up to speed. She was able to guide all of the needs that I have with confidence, intelligence, and excellent coordination of all of Huntsman's resources .
UofU Patient
December 19, 2020
HUNTSMAN CANCER CENTER
Dr. Soares is the best! Very concerned and answered any questions asked and very pleasant
UofU Patient
December 08, 2020
HUNTSMAN CANCER CENTER
Dr. Soares is an amazing physician. She is knowledgeable, always involves me in decisions about my care, and is very compassionate and caring. We are very thankful to have a physician who specializes in NET tumors.
UofU Patient
November 20, 2020
HUNTSMAN CANCER CENTER
I did not ask enough questions about the freezing treatment
UofU Patient
November 19, 2020
HUNTSMAN CANCER CENTER
Dr. Soares is very compassionate and knowledgeable about my condition. Would highly recommend her!
UofU Patient
November 15, 2020
HUNTSMAN CANCER CENTER
very good experience visiting with surgeon also with my oncologist. Dr Scaife is very thorough in explaining to me about the problem and the procedure she will be doing. also about the risks and the benefits. very kind and helpful.
UofU Patient
October 30, 2020
HUNTSMAN CANCER CENTER
had to reschedule appt due to the doctor running late
UofU Patient
October 27, 2020
HUNTSMAN CANCER CENTER
Dr. Soares was clear, concise, and most importantly, agreed to take on my case. :-)
UofU Patient
October 05, 2020
HUNTSMAN CANCER CENTER
Dr. Soares was very open and helpful. She and her staff were kind and competent.
UofU Patient
September 25, 2020
HUNTSMAN CANCER CENTER
Very blessed to have Dr Soares as my physician. She is very compassionate and and I am confident in her skills & knowledge of my condition.
UofU Patient
September 25, 2020
HUNTSMAN CANCER CENTER
Dr Soares is an outstanding provider. I feel that she treats the whole person, body, mind, and spirit!
UofU Patient
September 14, 2020
HUNTSMAN CANCER CENTER
great job
UofU Patient
September 11, 2020
HUNTSMAN CANCER CENTER
We LOVE Dr. Soares
UofU Patient
August 31, 2020
HUNTSMAN CANCER CENTER
Dr Soares is an amazing physician. She is kind, compassionate and very knowledgeable about NET tumors. I feel very blessed to have her as my physician.
UofU Patient
August 20, 2020
HUNTSMAN CANCER CENTER
My care providers were great about answering my questions & explaining things to me.
UofU Patient
August 08, 2020
HUNTSMAN CANCER CENTER
my doctor was excellent!! she explained things to me if I didn't understand.
Dr. Heloisa Soares is a medical oncologist with a focus in GI cancers and neuroendocrine tumors. She is an assistant professor at the Huntsman Cancer Institute (HCI) at University of Utah. Dr. Soares received her medical degree at Faculdade de Medicine do ABC in Brazil, where she was born. She completed her residency training at the Mount Sinai Medical Center of Florida and her hematology-oncology fellowship training and PhD in molecular biology at UCLA. Dr. Soares has neuroendocrine tumors and gastrointestinal (GI) cancers as the major focus of her research and clinical activities. She serves as the co-physician leader in the GI Clinical Trials Research Group at HCI. In 2019, she was elected as a member of the board of directors for The North American Neuroendocrine Tumor Society (NANETS), where she is also a member of the guidelines and communications committees. Additionally, she is a member of the NCI NET taskforce and member of SWOG and NRG cooperative groups. In 2018, Dr. Soares was named one of 40 Under 40 in Cancer, an awards program identifying and recognizing the contributions being made across the field of oncology by individuals under the age of 40 years old by the he Lynx Group™ and McGivney Global Advisors. Dr. Soares was awarded the NANETS 2020 Theranostics Investigator Scholarship (NTIG).
Dr. Soares is a passionate advocate to patients and has, along many other patient-centered activities, volunteered at the ASCO Advocacy Summit on Capital Hill and had the opportunity to meet members of congress and advocate to improve patient care.
You can follow her on twitter as @helops79
Academic Locations
Huntsman Cancer Institute Research North
801-585-0255
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor (Clinical) |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Medical Oncology) Educational Commission for Foreign Medical Graduates |
Research Interests
- GI Cancer
- Hepato-Pancreato-Biliary Cancers
- Gastrointestinal Cancers
- Neuroendocrine Tumors
Selected Publications - Journal Articles
Journal Article
- Loaiza-Bonilla A, Benson AB 3rd, Grothey A, Karimi M, Klempner SJ, Lin D, Mahtani R, Soares HP (2021). Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group. (Epub ahead of print) Oncologist.
- Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC, from the Carcinoid Syndrome Control Collaborative (2020). Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas, 49(9), 1123-1130.
- Kim R, Sanoff H, Poklepovic A, Soares H, Kim J, Lyu J, Liu Y, Kim D (2020). A multi-institutional phase II trial of regorafenib in refractory advanced biliary tract cancer. Accepted. . Cancer.
- Saif MW, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Ramirez RA, Halfdanarson TR, Beveridge TJR, Mirakhur B, Nagar SP, Soares HP (2019). Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol, 10(4), 647-687.
- Al-Toubah T, Schell M, Cives M, Zhou JM, Soares H, Strosberg JR (2019). A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Neuroendocrinology, doi: 10.1159/000502383.
- Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R (2018). Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs, 37(3), 473-481.
- Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, El-Khoueiry A, Feng M, Katz MHG, Primrose J, Soares HP, Valle J, Maithel SK (2019). Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol, 37(12), 1015-1027.
- Nemunaitis JM, Brown-Glabeman U, Soares H, Belmonte J, Liem B, Nir I, Phuoc V, Gullapalli RR (2018). Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. BMC Cancer, 18(1), 665.
- Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod HL, Cavallari LH (2018). Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp Clin Trials, 68, 7-13.
- Cives M, Anaya DA, Soares H, Coppola D, Strosberg J (2017). Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors. J Natl Cancer Inst, 110(3), 282-289.
- Wainberg ZA, Alsina M, Soares HP, Braa I, Britten CD, Del Conte G, Ezeh P, Houk B, Kern KA, Leong S, Pathan N, Pierce KJ, Siu LL, Vermette J, Tabernero J (2017). A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Target Oncol, 12(6), 775-785.
- Cives M, Soares HP, Strosberg J (2016). Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol, 28(4), 359-66.
- Wainberg ZA, Soares HP, Patel R, DiCarlo B, Park DJ, Liem A, Wang HJ, Yonemoto L, Martinez D, Laux I, Brennan M, Hecht JR (2015). Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers. Cancer Chemother Pharmacol, 76(1), 61-7.
- Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet-Smith J, Rozengurt E (2015). Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Mol Cancer Ther, 14(4), 1014-23.
- Ming M, Sinnett-Smith J, Wang J, Soares HP, Young SH, Eibl G, Rozengurt E (2014). Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells. PLoS ONE, 9(12), e114573.
- Rozengurt E, Soares HP, Sinnet-Smith J (2014). Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther, 13(11), 2477-88.
- Soares HP, Bayraktar S, Blaya M, Lopes G, Merchan J, Macintyre J, Mayo C, Green MR, Silva O, Levi J, Walker G, Rocha-Lima CM (2014). A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere. Cancer Chemother Pharmacol, 73(4), 839-45.
- Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E (2013). Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS ONE, 8(2), e57289.
- Djulbegovic B, Kumar A, Glasziou PP, Perera R, Reljic T, Dent L, Raftery J, Johansen M, Di Tanna GL, Miladinovic B, Soares HP, Vist GE, Chalmers I (2012). New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev, 10, MR000024.
- Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A (2012). Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol, 65(6), 602-9.
- Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ (2010). Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol, 64(6), 583-93.
- Soares HP, Lutzky J (2010). Velimogene aliplasmid. Expert Opin Biol Ther, 10(5), 841-51.
- Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, STOPIT-2 Study Group, Flynn DN, Elamin MB, Murad MH, Abu Elnour NO, Lampropulos JF, Sood A, Mullan RJ, Erwin PJ, Bankhead CR, Perera R, Ruiz Culebro C, You JJ, Mulla SM, Kaur J, Nerenberg KA, Schnemann H, Cook DJ, Lutz K, Ribic CM, Vale N, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Bucher HC, Nordmann AJ, Raatz H, da Silva SA, Tuche F, Strahm B, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Karanicolas PJ, Burns KE, Vandvik PO, Coto-Yglesias F, Chrispim PP, Ramsay T (2010). Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA, 303(12), 1180-7.
- Briel M, Lane M, Montori VM, Bassler D, Glasziou P, Malaga G, Akl EA, Ferreira-Gonzalez I, Alonso-Coello P, Urrutia G, Kunz R, Culebro CR, da Silva SA, Flynn DN, Elamin MB, Strahm B, Murad MH, Djulbegovic B, Adhikari NK, Mills EJ, Gwadry-Sridhar F, Kirpalani H, Soares HP, Abu Elnour NO, You JJ, Karanicolas PJ, Bucher HC, Lampropulos JF, Nordmann AJ, Burns KE, Mulla SM, Raatz H, Sood A, Kaur J, Bankhead CR, Mullan RJ, Nerenberg KA, Vandvik PO, Coto-Yglesias F, Schnemann H, Tuche F, Chrispim PP, Cook DJ, Lutz K, Ribic CM, Vale N, Erwin PJ, Perera R, Zhou Q, Heels-Ansdell D, Ramsay T, Walter SD, Guyatt GH (2009). Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). Trials, 10, 49.
- Trufelli DC, Bensi CG, Garcia JB, Narahara JL, Abro MN, Diniz RW, Miranda Vda C, Soares HP, Del Giglio A (2008). Burnout in cancer professionals: a systematic review and meta-analysis. Eur J Cancer Care (Engl), 17(6), 524-31.
- Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL (2008). Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med, 168(6), 632-42.
- Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF (2008). Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med, 49(3), 480-508.
- Tanvetyanon T, Soares HP, Djulbegovic B, Jacobsen PB, Bepler G (2007). A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol, 2(12), 1091-7.
- Rocha-Lima CM, Soares HP, Raez LE, Singal R (2007). EGFR targeting of solid tumors. Cancer Control, 14(3), 295-304.
- Behera M, Kumar A, Soares HP, Sokol L, Djulbegovic B (2007). Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control, 14(2), 160-6.
- Kumar A, Soares HP, Balducci L, Djulbegovic B, National Cancer Institute (2007). Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol, 25(10), 1272-6.
- Soares HP, Kumar A, Djulbegovic B (2006). Evidence profiles for breast cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 33(1), 87-9.
- Soares HP, Kumar A, Djulbegovic B (2006). Evidence profiles for lung cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 32(8), 652-5.
- Djulbegovic B, Soares HP, Kumar A (2006). What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms. Cancer Treat Rev, 32(7), 572-6.
- Kumar A, Soares HP, Djulbegovic B (2006). Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev, 32(7), 577-80.
- Kumar A, Soares HP (2006). Salvage radiotherapy increases survival in people with residual disease after chemotherapy for advance diffuse large cell lymphoma. Cancer Treat Rev, 32(6), 487-90.
- Kumar A, Soares H, Wells R, Clarke M, Hozo I, Bleyer A, Reaman G, Chalmers I, Djulbegovic B, Childrens Oncology Group (2005). Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group. BMJ, 331(7528), 1295.
- Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B (2005). Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA, 293(8), 970-8.
- Kumar A, Soares H, Serdarevic F (2005). Totality of evidence: one of the keys to better oncology management. J Oncol Manag, 14(1), 12-4.
- Weinschenker P, Soares HP, Clark O, Del Giglio A (2004). Immunocytochemical detection of epithelial cells in the bone marrow of primary breast cancer patients: a meta-analysis. Breast Cancer Res Treat, 87(3), 215-24.
- Megale Costa LJ, Soares HP, Gaspar HA, Trujillo LG, Santi PX, Pereira RS, de Santana TL, Pinto FN, del Giglio A (2004). Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol, 27(3), 304-6.
- Samano ES, Goldenstein PT, Ribeiro Lde M, Lewin F, Filho ES, Soares HP, del Giglio A (2004). Praying correlates with higher quality of life: results from a survey on complementary/alternative medicine use among a group of Brazilian cancer patients. Sao Paulo Med J, 122(2), 60-3.
- Soares HP, Daniels S, Kumar A, Clarke M, Scott C, Swann S, Djulbegovic B, Radiation Therapy Oncology Group (2004). Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ, 328(7430), 22-4.
- Fonseca FL, Soares HP, Manhani AR, Bendit I, Novaes M, Zatta SM, Arias V, Pinhal MA, Weinschenker P, del Giglio A (2002). Peripheral blood c-erbB-2 expression by reverse transcriptase-polymerase chain reaction in breast cancer patients receiving chemotherapy. Clin Breast Cancer, 3(3), 201-5.
- Pereira LP, Waisberg J, Andr EA, Zanoto A, Mendes Jnior JP, Soares HP (2002). Detection of Helicobacter pylori in gastric cancer. Arq Gastroenterol, 38(4), 240-6.
- Manhani AR, Manhani R, Soares HP, Bendit I, Lopes F, Nicoletti AG, Fonseca FL, Novaes M, Zatta SM, Arias V, Giralt S, del Giglio A (2001). CK-19 expression by RT-PCR in the peripheral blood of breast cancer patients correlates with response to chemotherapy. Breast Cancer Res Treat, 66(3), 249-54.
- del Giglio A, Soares HP, Caparroz C, Castro PC (2001). Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer, 89(11), 2301-8.